Stay in touch
Prime news from our network.
#read
Early detection of Parkinson's succeeds with new biomarker from Bochum
Researchers at Ruhr University Bochum and the biotech company betaSENSE have made significant progress in the early detection of Parkinson's disease. With the help of a new biomarker in the spinal fluid, the neurodegenerative disease can be reliably diagnosed at an early stage with an accuracy of over 90 per cent.
25/04/2025
The evidence is based on a misfolding of the protein alpha-synuclein, which leads to harmful deposits in the brain during the course of the disease. The study, published in the journal EMBO Molecular Medicine, is based on cerebrospinal fluid samples from two independent patient cohorts and was carried out using a patented, infrared-based sensor technology that was originally developed for the early detection of Alzheimer's disease. The so-called iRS platform has now been successfully transferred to Parkinson's disease. It recognises early molecular changes long before clinical symptoms such as movement disorders occur. This is of particular importance, as Parkinson's disease is usually only diagnosed in the late stages, when irreversible damage has already occurred in the brain. The new biomarker not only opens up diagnostic possibilities, but can also help to track the course of the disease and assess the effectiveness of new therapies in studies. It could therefore also play a key role in the development of future drugs.
Press release by "idw - Informationsdienst Wissenschaft" from 25 April 2025
The above texts, or parts thereof, were automatically translated from the original language text using a translation system (DeepL API).
Despite careful machine processing, translation errors cannot be ruled out.